Lv3
364 积分 2022-11-14 加入
Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 “DICIPLE” Phase III Trial
11天前
已完结
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group
21天前
已完结
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study
24天前
已完结
First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial
1个月前
已完结
Management guideline for the off-label use of medicine in China (2021)
1个月前
已完结
Comparison of patient data in parallel records: The sign-out sheet and the electronic medical record
1个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
1个月前
已完结
Modification and validation of the Birmingham Vasculitis Activity Score (version 3)
2个月前
已完结
Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides
2个月前
已完结
Modification and validation of the Birmingham Vasculitis Activity Score (version 3)
2个月前
已完结
皖公网安备34019202002308
